Imatinib and gastrointestinal stromal tumors: Where do we go from here?

Abstract

Imatinib has tremendously changed the treatment of gastrointestinal stromal tumors (GIST). Research is currently focusing on its optimal use and the mechanisms of resistance that may emerge. A multidisciplinary approach including medical oncologists, surgeons, radiologists, and pathologists is crucial for the optimal management of these patients. Moreover, imatinib treatment in GIST represents an extraordinary model to expand our knowledge on the molecular mechanisms that are basic to the effects of molecularly targeted therapies. This review summarizes the existing knowledge of the imatinib treatment in GIST and describes directions for further development. Copyright © 2005 American Association for Cancer Research.